Table 1.

Summary of the number of Sham and SDA animals included in each series of investigations

Cohort	Test	n(Sham)	n(SDA)
1	mRNA sequencing	5	5
2	PPI	14	13
	LI CTA	14	13
	NPE	7	6
	PE	7	7
3a	Low-dose Amph 1 mg/kg	7	7
3b	High-dose Amph 2 mg/kg	6	10
4	Neurochemistry	10	11
Pooled	BW	42	46
	CCK	42	46

Animals in Cohort 1 were used for next-generation mRNA sequencing and subsequent gene expression validation by quantitative RT-PCR. Animals in Cohort 2 were first tested in the paradigm of PPI and were then subjected to the test of LI in CTA. For the latter, Sham and SDA animals were equally distributed to NPE and PE subgroups. Animals in Cohort 3 were used to asses the sensitivity to the psychostimulant drug, Amph. A subcohort of animals (3a) was treated with 1 mg/kg Amph, whereas another subcohort (3b) was treated with 2 mg/kg Amph. Animals in Cohort 4 were used for postmortem analyses of dopamine neurochemistry using HPLC. Animals from all cohorts were pooled for the assessment of postsurgery body weight (BW) and for the verification of SDA completeness in a CCK satiation test. All animals were adult male Sprague-Dawley (Crl:CD) rats.